Teva Pharmaceutical Industries Limited (TEVA) Comments On Receipt Of First Paragraph IV Notice For COPAXONE® 40 Mg/Ml (Glatiramer Acetate Injection) Formulation
8/7/2014 11:09:10 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE® 40 mg/mL product from Dr. Reddy’s Laboratories, Inc. Teva will continue to vigorously defend its COPAXONE® intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of FDA approval of Dr. Reddy’s ANDA.
COPAXONE® 40 mg/mL is protected by two Orange Book patents that expire in 2030.
Help employers find you! Check out all the jobs and post your resume.
comments powered by